BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
The case for medical marijuana in epilepsy.
Authors: Edward Maa, Paige Figi
Epilepsia, June 2014
—
Charlotte, a little girl with SCN1A-confirmed Dravet syndrome, was recently featured in a special that aired on CNN. Through exhaustive personal research and assistance from a Colorado-based medical marijuana group (Realm of Caring), Charlotte’s mother started adjunctive thera…
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014
—
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…
The case for assessing cannabidiol in epilepsy
Authors: Maria Roberta Cilio, Elizabeth A. Thiele, Orrin Devinsky
Epilepsia, June 2014
—
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the ma…
Cannabis, the pregnant woman and her child: weeding out the myths.
Authors: S C Jaques, A Kingsbury, P Henshcke, C Chomchai, S Clews, J Falconer, M E Abdel-Latif, et al
Journal of Perinatology, June 2014
—
To review and summarise the literature reporting on cannabis use within western communities with specific reference to patterns of use, the pharmacology of its major psychoactive compounds, including placental and fetal transfer, and the impact of maternal cannabis use on preg…
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders.
Authors: Barbara S. Koppel, John C.M. Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, et al
Neurology, 29 April 2014
—
OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We gra…
Anandamide inhibits breast tumor-induced angiogenesis.
Authors: P. Picardi, E. Ciaglia, M. C. Proto, S. Pisanti
Translational Medicine, 8 April 2014
—
Breast cancer is one of the most frequently diagnosed malignancies and a leading cause of cancer death in women. Great advances in the treatment of primary tumors have led to a significant increment in the overall survival rates, however recurrence and metastatic disease, the…
Genetic variations in the human cannabinoid receptor gene are associated with happiness.
Authors: Masahiro Matsunaga , Tokiko Isowa, Kaori Yamakawa, Seisuke Fukuyama, Jun Shinoda, et al
PLoS One, 1 April 2014
—
Happiness has been viewed as a temporary emotional state (e.g., pleasure) and a relatively stable state of being happy (subjective happiness level). As previous studies demonstrated that individuals with high subjective happiness level rated their current affective states more…
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.
Authors: Itay Lotan, Therese Treves, Yaniv Roditi, Ruth Djaldetti
Clinical Neuropharmacology, March-April 2014
—
OBJECTIVE: The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess…
Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.
Authors: John M. McPartland, Geoffrey W. Guy, Vincenzo Di Marzo
PLoS One, 12 March 2014
—
BACKGROUND: The “classic” endocannabinoid (eCB) system includes the cannabinoid receptors CB1 and CB2, the eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes. An emerging literature documents the “eCB deficiency syndrome” as an etiology…
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic.
Authors: Ester Aso, Isidre Ferrer
Frontiers in Pharmacology, 5 March 2014
—
The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabino…
Cannabinoids for epilepsy.
Authors: David Gloss, Barbara Vickrey
Cochrane Database of Systematic Reviews, 5 March 2014
—
BACKGROUND: Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy. OBJECTIVES: To assess the efficacy and sa…
PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.
Authors: George R. Greer, Charles S. Grob, Adam L. Halberstadt
Journal of Psychoactive Drugs, January-March 2014
—
BACKGROUND: New Mexico was the first state to list post-traumatic stress disorder (PTSD) as a condition for the use of medical cannabis. There are no published studies, other than case reports, of the effects of cannabis on PTSD symptoms. The purpose of the study was to report…